Rapamycin inhibits the mammalian target of the rapamycin (mTOR) signaling pathway to downregulate TREM2 (Triggering receptor expressed on myeloid cells 2) in microglia and reduce Aβ plaque clearance in AD mice (5XFAD),43 we also tested the effect of the rapamycin analog AP21967, known as rapalog (Log), which binds poorly to mTOR and thus is relatively nontoxic to cells but can bind to the FRB domain with equal affinity as rapamycin due to a compensatory cavity‐forming mutation, K2095P, introduced in the FRB domain.44 The gene discussed is MTOR; the disease is Alzheimer disease.